OBJECTIVE: Arthritis and valvular carditis coexist in several human rheumatic diseases, including systemic lupus erythematosus, rheumatic fever, and rheumatoid arthritis. T cell receptor-transgenic K/BxN mice develop spontaneous autoantibody-associated arthritis and valvular carditis. The common Fc receptor γ (FcRγ) signaling chain is required for carditis to develop in K/BxN mice. FcRγ pairs with numerous receptors in a variety of cells. The aim of this study was to identify the FcRγ-associated receptors and Fcγ receptor (FcγR)-expressing cells that mediate valvular carditis in this model. METHODS: We bred K/BxN mice lacking the genes that encode activating Fcγ receptors (FcγRI, FcγRIII, and FcγRIV), and we assessed these mice for valvular carditis. We similarly evaluated complement component C3-deficient K/BxN mice. Immunohistochemistry, bone marrow transplantation, and macrophage depletion were used to define the key FcRγ-expressing cell type. RESULTS: Genetic deficiency of only one of the activating Fcγ receptors did not prevent carditis, whereas deficiency of all 3 activating Fcγ receptors did. Further analysis demonstrated that FcγRIII and FcγRIV were the key drivers of valve inflammation; FcγRI was dispensable. C3 was not required. FcRγ expression by radioresistant cells was critical for valvular carditis to develop, and further analysis indicated that macrophages were the key candidate FcγR-expressing effectors of carditis. CONCLUSION: FcγRIII and FcγRIV act redundantly to promote valvular carditis in K/BxN mice with systemic autoantibody-associated arthritis. Macrophage depletion reduced the severity of valve inflammation. These findings suggest that pathogenic autoantibodies engage Fcγ receptors on macrophages to drive valvular carditis. Our study provides new insight into the pathogenesis of cardiovascular inflammation in the setting of autoantibody-associated chronic inflammatory diseases.
OBJECTIVE:Arthritis and valvular carditis coexist in several humanrheumatic diseases, including systemic lupus erythematosus, rheumatic fever, and rheumatoid arthritis. T cell receptor-transgenic K/BxN mice develop spontaneous autoantibody-associated arthritis and valvular carditis. The common Fc receptor γ (FcRγ) signaling chain is required for carditis to develop in K/BxN mice. FcRγ pairs with numerous receptors in a variety of cells. The aim of this study was to identify the FcRγ-associated receptors and Fcγ receptor (FcγR)-expressing cells that mediate valvular carditis in this model. METHODS: We bred K/BxN mice lacking the genes that encode activating Fcγ receptors (FcγRI, FcγRIII, and FcγRIV), and we assessed these mice for valvular carditis. We similarly evaluated complement component C3-deficient K/BxN mice. Immunohistochemistry, bone marrow transplantation, and macrophage depletion were used to define the key FcRγ-expressing cell type. RESULTS:Genetic deficiency of only one of the activating Fcγ receptors did not prevent carditis, whereas deficiency of all 3 activating Fcγ receptors did. Further analysis demonstrated that FcγRIII and FcγRIV were the key drivers of valve inflammation; FcγRI was dispensable. C3 was not required. FcRγ expression by radioresistant cells was critical for valvular carditis to develop, and further analysis indicated that macrophages were the key candidate FcγR-expressing effectors of carditis. CONCLUSION: FcγRIII and FcγRIV act redundantly to promote valvular carditis in K/BxN mice with systemic autoantibody-associated arthritis. Macrophage depletion reduced the severity of valve inflammation. These findings suggest that pathogenic autoantibodies engage Fcγ receptors on macrophages to drive valvular carditis. Our study provides new insight into the pathogenesis of cardiovascular inflammation in the setting of autoantibody-associated chronic inflammatory diseases.
Authors: A S Korganow; H Ji; S Mangialaio; V Duchatelle; R Pelanda; T Martin; C Degott; H Kikutani; K Rajewsky; J L Pasquali; C Benoist; D Mathis Journal: Immunity Date: 1999-04 Impact factor: 31.745
Authors: Cecilia P Chung; Annette Oeser; Paolo Raggi; Tebeb Gebretsadik; Ayumi K Shintani; Tuulikki Sokka; Theodore Pincus; Ingrid Avalos; C Michael Stein Journal: Arthritis Rheum Date: 2005-10
Authors: W L Hazenbos; J E Gessner; F M Hofhuis; H Kuipers; D Meyer; I A Heijnen; R E Schmidt; M Sandor; P J Capel; M Daëron; J G van de Winkel; J S Verbeek Journal: Immunity Date: 1996-08 Impact factor: 31.745
Authors: David M Lee; Daniel S Friend; Michael F Gurish; Christophe Benoist; Diane Mathis; Michael B Brenner Journal: Science Date: 2002-09-06 Impact factor: 47.728
Authors: Lee A Meier; Jessica L Faragher; Victoria Osinski; Jennifer L Auger; Rochus Voeller; Aubyn Marath; Bryce A Binstadt Journal: J Immunol Date: 2022-06-03 Impact factor: 5.426
Authors: Lee A Meier; Jennifer L Auger; Brianna J Engelson; Hannah M Cowan; Elise R Breed; Mayra I Gonzalez-Torres; Joshua D Boyer; Mayank Verma; Aubyn Marath; Bryce A Binstadt Journal: Circulation Date: 2018-01-31 Impact factor: 29.690
Authors: Marieke F Fransen; Hreinn Benonisson; Wendy W van Maren; Heng Sheng Sow; Cor Breukel; Margot M Linssen; Jill W C Claassens; Conny Brouwers; Jos van der Kaa; Marcel Camps; Jan Willem Kleinovink; Kelly K Vonk; Sandra van Heiningen; Ngaisah Klar; Lianne van Beek; Vanessa van Harmelen; Lucia Daxinger; Kutty S Nandakumar; Rikard Holmdahl; Chris Coward; Qingshun Lin; Sachiko Hirose; Daniela Salvatori; Thorbald van Hall; Cees van Kooten; Piero Mastroeni; Ferry Ossendorp; J Sjef Verbeek Journal: J Immunol Date: 2018-03-09 Impact factor: 5.422
Authors: Tamás Németh; Krisztina Futosi; Marcell Szabó; Petra Aradi; Takashi Saito; Attila Mócsai; Zoltán Jakus Journal: Front Immunol Date: 2019-02-25 Impact factor: 7.561
Authors: April M Huseby Kelcher; Carly A Baehr; Fatima A Hamid; Geoffrey T Hart; Marco Pravetoni Journal: J Immunol Date: 2021-07-19 Impact factor: 5.426
Authors: Irene Di Ceglie; Giuliana Ascone; Niels A J Cremers; Annet W Sloetjes; Birgitte Walgreen; Thomas Vogl; Johannes Roth; J Sjef Verbeek; Fons A J van de Loo; Marije I Koenders; Peter M van der Kraan; Arjen B Blom; Martijn H J van den Bosch; Peter L E M van Lent Journal: Arthritis Res Ther Date: 2018-05-02 Impact factor: 5.156